Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ascendis Pharma A/S - Ordinary Share
(NQ:
ASND
)
245.38
+0.90 (+0.37%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
403,461
Open
244.48
Bid (Size)
98.20 (200)
Ask (Size)
392.76 (200)
Prev. Close
244.48
Today's Range
243.81 - 247.90
52wk Range
150.89 - 250.74
Shares Outstanding
57,152,295
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
April 13, 2026
In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL...
Via
MarketMinute
Topics
Economy
Agriculture Stock Up 53% Draws $12 Million Bet. Here's What Long-Term Investors Should Know
↗
March 20, 2026
This agribusiness firm delivers grain, renewables, and plant nutrient solutions to commercial and industrial clients worldwide.
Via
The Motley Fool
Topics
Regulatory Compliance
Performance
YTD
+15.0%
+15.0%
1 Month
+10.6%
+10.6%
3 Month
+13.8%
+13.8%
6 Month
+19.6%
+19.6%
1 Year
+52.3%
+52.3%
More News
Read More
Ascendis (ASND) Q4 2025 Earnings Call Transcript
↗
February 23, 2026
Via
The Motley Fool
Topics
Earnings
Ascendis Pharma (NASDAQ:ASND) Shares Drop After Q4 Earnings Miss on Wider-Than-Expected Loss
↗
February 11, 2026
Via
Chartmill
Topics
Earnings
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
↗
February 22, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
↗
February 22, 2026
Via
The Motley Fool
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction
↗
February 22, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum
↗
January 28, 2026
Via
Chartmill
Earnings Scheduled For November 12, 2025
↗
November 12, 2025
Via
Benzinga
A Look Ahead: Ascendis Pharma's Earnings Forecast
↗
November 11, 2025
Via
Benzinga
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges
↗
February 22, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript
↗
February 11, 2026
Via
The Motley Fool
Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan
↗
December 25, 2025
Via
Chartmill
Why Dyne Therapeutics Stock Was Crushing it This Week
↗
November 21, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility
November 19, 2025
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Supply Chain
Ascendis (ASND) Q3 2025 Earnings Call Transcript
↗
November 13, 2025
Via
The Motley Fool
Topics
Earnings
Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
↗
November 12, 2025
Via
Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
↗
October 29, 2025
Via
Benzinga
Looking Into Ascendis Pharma AS's Recent Short Interest
↗
October 21, 2025
Via
Benzinga
Ascendis Pharma A/S - ADR (NASDAQ:ASND) Shows Strong Growth Momentum in Technical and Fundamental Analysis
↗
October 14, 2025
Via
Chartmill
What Does the Market Think About Ascendis Pharma AS?
↗
September 29, 2025
Via
Benzinga
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
↗
September 25, 2025
Via
Benzinga
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment
↗
September 08, 2025
Via
Benzinga
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
↗
September 08, 2025
Via
Benzinga
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
↗
September 04, 2025
Via
Benzinga
Frequently Asked Questions
Is Ascendis Pharma A/S - Ordinary Share publicly traded?
Yes, Ascendis Pharma A/S - Ordinary Share is publicly traded.
What exchange does Ascendis Pharma A/S - Ordinary Share trade on?
Ascendis Pharma A/S - Ordinary Share trades on the Nasdaq Stock Market
What is the ticker symbol for Ascendis Pharma A/S - Ordinary Share?
The ticker symbol for Ascendis Pharma A/S - Ordinary Share is ASND on the Nasdaq Stock Market
What is the current price of Ascendis Pharma A/S - Ordinary Share?
The current price of Ascendis Pharma A/S - Ordinary Share is 245.38
When was Ascendis Pharma A/S - Ordinary Share last traded?
The last trade of Ascendis Pharma A/S - Ordinary Share was at 04/20/26 04:00 PM ET
What is the market capitalization of Ascendis Pharma A/S - Ordinary Share?
The market capitalization of Ascendis Pharma A/S - Ordinary Share is 14.02B
How many shares of Ascendis Pharma A/S - Ordinary Share are outstanding?
Ascendis Pharma A/S - Ordinary Share has 14B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.